• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Neurotech International

Neurotech International

ASX:NTI

  • Home
  • Corporate
    • Board and Management
    • Corporate Directory
    • Corporate Governance
  • Development Programs
    • Biopharmaceutical Trials
    • Combination Therapy
    • Pathways to Commercialisation
    • Mente Technology
  • Investors
    • Investor Dashboard
    • ASX Announcements
    • Company Reports
    • Presentations
    • Research
    • News & Media
  • Contact

News &
Media

  • Neurotech International with Proactive at the ASX Small and Mid-Cap Conference

    19 September 2022
    Proactive Investors

    Neurotech International Executive Director Dr Tom Duthy speaks with Proactive at the ASX Small and Mid-Cap Conference September 2022.

    View More
  • Cannabis extract has Autism success

    3 September 2022
    The Post

    View More
  • New Hope for Children Living with Autism. Channel 7 NEWS 28 August 2022

    28 August 2022
    Stocks Down Under
    View More
  • Neurotech International appoints industry expert during key phase of growth

    18 August 2022
    Stockhead

    Neurotech International has made key appointments and changes to its board as it focuses on its developing and commercialising neurological solutions, including a cannabis breakthrough for paediatric autism.

    View More
  • Gerald Quigley, short discussion on 4RO Rockhampton regarding Autism

    2 August 2022
    4RO
    View More
  • Gerald Quigley, Co-host of The House of Wellness on 6PR discusses exciting new developments in Autism Spectrum Disorder (ASD) field linked to Cannabis, including a particular extract called NTI164.

    30 July 2022
    6PR
    View More
  • Stocks Down Under Interview with Neurotech International (ASX:NTI)

    27 July 2022
    Stocks Down Under
    View More
  • Neurotech eyes Phase II/III trial and FDA approval after cannabis breakthrough on paediatric autism

    22 July 2022
    Stockhead

    Neurotech International (ASX:NTI) has recently announced ground-breaking results with respect to the safety, tolerability, and efficacy of NTI164 in Autism Spectrum Disorder (ASD) patients.

    View More
  • Neurotech Releases ASD Medical Cannabis Study Results

    12 July 2022
    The Hemp Gazette

    Australia’s Neurotech International Limited (ASX: NTI) has announced what it says are successful outcomes of its medical cannabis formulation on key behavioural issues impacting kids with autism.

    View More
Previous
1 2 3 4 5
Next

Footer

Suite 5 CPC, 145 Stirling Highway
Nedlands WA 6009
Australia

moc.l1675267020anoit1675267020anret1675267020nihce1675267020torue1675267020n@ofn1675267020i1675267020

+61 (8) 9389 3130

Subscribe to our latest announcements

Name*
This field is for validation purposes and should be left unchanged.

Copyright © 2023 Neurotech International • Site by White Noise Communications

Download prospectus